Novartis's Menveo gains first approval, in the US
This article was originally published in Scrip
Executive Summary
Novartis's quadrivalent conjugated meningococcal vaccine Menveo (meningococcal (groups A, C, W-135) oligosaccharide diphtheria CRM197 conjugate vaccine) has been approved in the US – its first market – for active immunisation to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11 to 55 years.